120
Participants
Start Date
December 17, 2020
Primary Completion Date
September 12, 2022
Study Completion Date
September 12, 2022
Previously treated with EN3835 up to 1.74 mg or Placebo in EN3835-210 or the pivotal phase 3 studies
No treatment to be administered - Observational only
Endo Clinical Trial Site #10, Stony Brook
Endo Clinical Trial Site #12, Indiana
Endo Clinical Trial Site #30, Altoona
Endo Clinical Trial Site #5, State College
Endo Clinical Trial Site #3, Danville
Endo Clinical Trial Site #29, Durham
Endo Clinical Trial Site #20, Lawrenceville
Endo Clinical Trial Site #21, Newnan
Endo Clinical Trial Site #24, Stockbridge
Endo Clinical Trial Site #26, Dalton
Endo Clinical Trial Site #4, Winter Park
Endo Clinical Trial Site #19, Fort Lauderdale
Endo Clinical Trial Site #1, Tampa
Endo Clinical Trial Site #2, Clearwater
Endo Clinical Trial Site #16, Birmingham
Endo Clinical Trial Site #9, Mobile
Endo Clinical Trial Site #13, Dayton
Endo Clinical Trial Site #23, Oak Brook
Endo Clinical Trial Site #28, Oak Brook
Endo Clinical Trial Site #15, Plano
Endo Clinical Trial Site #18, Plano
Endo Clinical Trial Site #6, Bedford
Endo Clinical Trial Site #17, Bellaire
Endo Clinical Trial Site #22, Laredo
Endo Clinical Trial Site #27, Georgetown
Endo Clinical Trial Site #25, Tucson
Endo Clinical Trial Site #11, Pasadena
Endo Clinical Trial Site #14, La Mesa
Endo Clinical Trial Site #8, Encinitas
Endo Clinical Trial Site #7, Huntington Beach
Lead Sponsor
Endo Pharmaceuticals
INDUSTRY